The NordICC Study is the first randomized controlled trial to test colonoscopy as a screening modality for colorectal cancer. The effect of colonoscopy was lower than previously thought.

We talk with the P.I., Dr. Michael Bretthauer, what to make of the study and whether (and in which areas) we should remain doubtful. Dr. Bretthauer is a professor of medicine at the University of Oslo.

References:

• M Bretthauer et al. N Engl J Med. 2022 Oct 27;387(17):1547-1556. https://pubmed.ncbi.nlm.nih.gov/36214590/
• RL Siegel et al. CA Cancer J Clin. 2022;72:7-33. https://pubmed.ncbi.nlm.nih.gov/35020204/
• Ø Holme et al. Ann Intern Med. 2018;168:775-82. https://pubmed.ncbi.nlm.nih.gov/29710125/
• Global Cancer Observatory, https://gco.iarc.fr/
• M Bretthauer et al. Ann Int Med. 2017;166:139-40. https://pubmed.ncbi.nlm.nih.gov/27820949/
• USPSTF: JAMA. 2021;325(19):1965-77 https://jamanetwork.com/journals/jama/fullarticle/2779985
• E Quintero et al. N Engl J Med. 2012;366:697-706 https://pubmed.ncbi.nlm.nih.gov/22356323/
• AB Knudsen et al. JAMA. 2021;325(19):1998-2011 https://pubmed.ncbi.nlm.nih.gov/34003219/
• Ex. calculator: https://ccrisktool.cancer.gov/calculator.html
• LM Helsingen et al. BMJ. 2019367:l5515. https://pubmed.ncbi.nlm.nih.gov/31578196/

YouTube: https://youtu.be/mTxKbbcx9BY

Hosted on Acast. See acast.com/privacy for more information.